A large new study has found that heart risks begin to return as soon as six months after stopping the drug and may be almost ...

Analysts had expected the introduction of oral GLP-1 weight-loss drugs to have an adverse effect on the food industry ...

Brianna "Chickenfry" LaPaglia, in a March 10 TikTok video, got candid about the growing use of GLP-1 weight loss medication.

Retrospective study finds link between blockbuster drugs and longer survival ...

Here's what happens to your heart, liver, skin, and more.

By Nancy Lapid March 4 (Reuters) - Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent new substance use disorders and alleviate existing addictions, according to findings from a large ...

People who take GLP-1 medications for several years may face a higher risk of developing osteoporosis, gout, and osteomalacia, according to new research presented Monday at the an ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Feb 23 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, ...

A one-month, four-dose pen could reduce injector component consumption and assembly cycles, addressing a key constraint that has limited GLP-1 category supply reliability. Consolidation of doses may ...

The change, advocates argue, would curb rising obesity rates, reduce health care disparities and save on health care costs.